Roger W. Quan, PhD

Placeholder Person Graphic
Bright Path Laboratories
Regulatory Affairs Advisor
Roger Quan, PhD, is a Regulatory Affairs Consultant for Regtel Consulting, LLC. Last year, Roger left Abbott/AbbVie after a 20-year career that included stints in R&D process chemistry, manufacturing, and regulatory affairs. During his 14 years in the regulatory affairs group, Roger supported many developmental and marketed products including AbbVie’s first oncology product. In the last seven years, he managed a group of regulatory professionals that supported small molecule, biologic, and device programs. Roger received a BS in chemistry from the University of Michigan and a PhD in chemistry from California Institute of Technology. After spending two years as a post-doctoral scholar at Harvard, Roger worked at Amoco Chemical Company for three years developing polymerization catalysts. He has been an ISPE member since 2018.

Related Articles

A Patient-Centric Review of ICH Q6A and ICH6B
Online Exclusives
A Patient-Centric Review of ICH Q6A and ICH6B

The ICH Quality Discussion Group (QDG) has recommended contemporizing the specification setting guidelines ICH Q6A and Q6B. This provides an excellent opportunity to update ICH Q6A/B to align and work in a complementary manner with the science-, risk/knowledge-based concepts in ICH Q8–Q12. The ISPE Pharmaceutical Quality Lifecycle Implementation (PQLI) Patient-Centric Specification working...